Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis
Background More than 10 years have elapsed since human papillomavirus (HPV)
vaccination was implemented. We did a systematic review and meta-analysis of the …
vaccination was implemented. We did a systematic review and meta-analysis of the …
Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis
Background Human papillomavirus (HPV) vaccination programmes were first implemented
in several countries worldwide in 2007. We did a systematic review and meta-analysis to …
in several countries worldwide in 2007. We did a systematic review and meta-analysis to …
Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data
Objective To measure the effect on genital warts of the national human papillomavirus
vaccination programme in Australia, which started in mid-2007. Design Trend analysis of …
vaccination programme in Australia, which started in mid-2007. Design Trend analysis of …
Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study
DM Gertig, JML Brotherton, AC Budd, K Drennan… - BMC medicine, 2013 - Springer
Background Australia was one of the first countries to introduce a publicly funded national
human papillomavirus (HPV) vaccination program that commenced in April 2007, using the …
human papillomavirus (HPV) vaccination program that commenced in April 2007, using the …
Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study
T Palmer, L Wallace, KG Pollock, K Cuschieri… - bmj, 2019 - bmj.com
Objective To quantify the effect on cervical disease at age 20 years of immunisation with
bivalent human papillomavirus (HPV) vaccine at age 12-13 years. Design Retrospective …
bivalent human papillomavirus (HPV) vaccine at age 12-13 years. Design Retrospective …
Present status of human papillomavirus vaccine development and implementation
R Herrero, P González, LE Markowitz - The Lancet Oncology, 2015 - thelancet.com
Oncogenic human papillomavirus (HPV) infection is the cause of nearly all cervical cancers
and a proportion of other anogenital and oropharyngeal cancers. A bivalent vaccine …
and a proportion of other anogenital and oropharyngeal cancers. A bivalent vaccine …
Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program
L Baandrup, M Blomberg, C Dehlendorff… - Sexually transmitted …, 2013 - journals.lww.com
Background Approximately 90% of genital warts (GWs) are caused by human
papillomavirus (HPV) types 6 and 11. Denmark has provided the quadrivalent HPV vaccine …
papillomavirus (HPV) types 6 and 11. Denmark has provided the quadrivalent HPV vaccine …
Fall in genital warts diagnoses in the general and indigenous Australian population following implementation of a national human papillomavirus vaccination program …
Background. Human papillomavirus (HPV) vaccination targeting females aged 12–13 years
commenced in Australia in 2007, with catch-up vaccination of females aged 13–26 years …
commenced in Australia in 2007, with catch-up vaccination of females aged 13–26 years …
Genital warts
M Steben, SM Garland - Best practice & research Clinical obstetrics & …, 2014 - Elsevier
Anogenital warts (AGWs) are a very common disease. They are caused mostly by low-risk
human papillomaviruses (HPV) 6 and 11, particularly the former. Clinical presentation is …
human papillomaviruses (HPV) 6 and 11, particularly the former. Clinical presentation is …
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®): A Review of Its Use in the Prevention of Premalignant Anogenital …
PL McCormack - Drugs, 2014 - Springer
Quadrivalent human papillomavirus (HPV)[types 6, 11, 16, 18] recombinant vaccine
(Gardasil®; Silgard®) is composed of virus-like particles formed by self-assembly of …
(Gardasil®; Silgard®) is composed of virus-like particles formed by self-assembly of …